

# Lung cancer diagnostics from Roche oncology:

Your partner in the journey towards diagnostic



**Initial assessment**

**Imaging**

**CEA, CYFRA21-1, NSE, ProGRP, SCC**  
Added to imaging and histology as an aid in diagnosis to assess the likelihood of malignancy in case of clinical symptoms or indeterminate pulmonary nodules<sup>1-5</sup>

**Cancer Center**

CT Biopsy


**Differential diagnosis and staging<sup>6</sup>**

**H&E**  
Histological classification


**IHC**  
Sub-typing

**ProGRP for differential diagnosis (SCLC)<sup>7</sup>**

**Prognosis**



**Prediction and treatment decision**



**Monitoring**

**EGFR**  
Therapy monitoring EGFR+ patients using liquid biopsy<sup>10</sup>

**CEA, CYFRA21-1, NSE, ProGRP, SCC**  
Therapy monitoring with a single or combination of biomarkers (follow initially elevated biomarkers)<sup>9,11-17</sup>

**CGP**  
Liquid biopsy for therapy monitoring

## Digital solutions

Immunochemistry (IC)

Polymerase Chain Reaction (PCR)

Hematoxylin & Eosin Stain (H&E)/Immunohistochemistry (IHC)

Digital solutions

Imaging

Next Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP)\*

\* Foundation Medicine Inc. (FMI) for clinical use.

Published by:  
Roche Diagnostics (Thailand) Co., Ltd:  
18-19th Floor, Rasa Tower Building  
555 Paholyothin Rd., Chatuchak, Bangkok 10900  
Thailand

ค่าเดือน โฆษณาโดยตรงต่อผู้ประกอบวิชาชีพทางการแพทย์และสาธารณสุข ที่ได้รับการยกเว้น  
โดยไม่ต้องขออนุญาต

อ่านค่าเดือนในฉลากและเอกสาร  
กำกับเครื่องมือแพทย์ก่อนใช้

MC-TH-011107  
AN 6701429  
Valid Till 12/11/2026

- <sup>1</sup> Molina R, Holdenrieder S, Auge JM, Schalthorn A, Hatz R, Stieber P. (2009/2010). Diagnostic relevance of circulating biomarkers in patients with lung cancer. *Cancer Biomarkers* 6, 163-178.
- <sup>2</sup> Molina R, Auge JM, Bosch X, Escudero JM, Vinola N, Marrades R, Ramirez J, Carcereny E, Filella X. (2009). Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. *Tumor Biology*, 30, 121-129.
- <sup>3</sup> Molina R, Marrades RM, Auge JM, Escudero JM, Vinolas N, Reguart N, Ramirez J, Filella X, Molins L, Agusti A. (2016). Assessment of a combined panel of six serum tumor markers for lung cancer. *Am. J. Resp. Crit. Care Med.* 193, 427-437.
- <sup>4</sup> Zhi X, Yuankai S, Jinming Y. (2015). Chinese guidelines on the diagnosis and treatment of primary lung cancer. *Chin J Oncol.* 37, Vol. 1.
- <sup>5</sup> Muley T, Schneider MA, Meister M, et al. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan. *Tumour Biol.* 2023 Oct 12. doi: 10.3233/TUB-220042.
- <sup>6</sup> Warth A, Muley T, Herpel E, Meister M, Herth FJF, Schirmacher P, Weichert W, Hoffmann H, Schnabel PA (2012). Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small cell lung cancer biopsies. *Histopathology* 61, 1017-1025.
- <sup>7</sup> Korse CM, Holdenrieder S, Zhi X-y, et al. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. *Clin Chim Acta* 2015;438:388-395.
- <sup>8</sup> Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. *Modern Pathology* 2012; 5, S18-S30.
- <sup>9</sup> Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi, M. (2006). Decline in Serum Carcinoembryonic Antigen and Cytokeratin 19 Fragment During Chemotherapy Predicts Objective Response and Survival in Patients With Advanced Nonsmall Cell Lung Cancer. *Cancer* 107, 2842-2849.
- <sup>10</sup> Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P. (2014). Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. *Cancer* 120, 3896-901.
- <sup>11</sup> Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami, H., Nakajima, T., Endo, M., Yamamoto, N. (2013). Prognostic impact of serum CYFRA21-1 in patients with advanced lung adenocarcinoma: a retrospective study. *BMC Cancer* 13, 354.
- <sup>12</sup> Vollmer RT, Govindan R, Graziano, SL, Gamble G, Garst J, Kelley MJ, Christenson RH (2003). Serum CYFRA21-1 in advanced stage non-small cell lung cancer: an early measure of response. *Clin. Cancer Res.* 9, 1728-1733.
- <sup>13</sup> Pang L, Wang J, lang Y, Chen L. Decreased levels of serum cytokeratin 19 fragment CYFRA 21 1 predict objective response to chemotherapy in patients with non-small cell lung cancer. (2013). *Experimental and therapeutic medicine* 6: 355-360.
- <sup>14</sup> Naito T, Ito I, Watanabe R, Shukuya T, Kenmotsu H, Tsuya A, Nakamura Y, Murakami H, Kaira K, Takahashi T, Kameya T, Nakajima T, Endo M, Yamamoto N. (2012). Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. *Lung Cancer* 76, 439-444.
- <sup>15</sup> Wojcik E, Kulpa JK, SAS-Korczynska B, Korezeniowski S, Jakubowicz J (2008). ProGRP and NSE in therapy monitoring in patients with small-cell lung cancer. *Anticancer Res.* 28, 3027-3034.
- <sup>16</sup> Muley T, Herth FJ, Heussel CP, et al. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. *Tumour Biol.* 2023; Oct 12 doi: 10.3233/TUB-230016.
- <sup>17</sup> Mang A, Zou W, Rolny V, et al. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150. *Tumour Biol.* 2023 Aug 2. doi: 10.3233/TUB-230001.